This content is from: Premium Healthcare Hedge Funds Are in Critical Condition Many suffered additional huge losses in April and are now down well over 50 percent from their peaks. By Stephen Taub May 11, 2022
This content is from: Portfolio Why the Michigan Retirement System Is Still Bullish on Cathie Wood ARK’s founder is a rare “conviction investor” among growth managers, says the retirement system’s Jack Behar. By Hannah Zhang April 04, 2022
This content is from: Premium Healthcare Hedge Funds Shine as This Year’s Winning Strategy Managers are plowing money into oncology and genomics-oriented companies — and reaping rewards. By Michelle Celarier October 08, 2018
What Is Pharmacogenomics? The convergence of the life sciences, information technology, high-speed computation and genomics has created a unique industry that may well be among the most attractive investment opportunity for investors today. By Udayan Gupta September 13, 2010
This content is from: Portfolio How to Profit from Faster FDA and Better Science Buoyed by advances in genomics and a speedier FDA, health care investors are seeking moneymaking opportunities among pharmaceuticals companies developing expensive, new drugs. By Fran Hawthorne August 01, 2012
Why Health Care Is Looking Healthier Tony Butler, managing director and senior health care analyst at Barclays Capital, talks to Institutional Investor contributor Fran Hawthorne about investing in health care. By Fran Hawthorne September 09, 2010
